With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

The risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is and with GLP-1 RAs versus DPP-4is.

Recent medical research reveals promising developments in the treatment of patients suffering ... focused specifically on their effects on COPD exacerbations among diabetic patients.

So a COPD exacerbation is a period where people with COPD will notice an acute deterioration in their symptoms. And these will probably last a few days, and they may experience shortness of breath ...

“This could influence treatment decisions and improve respiratory health in this high-risk population.” “GLP-1 medications might help lower COPD exacerbation risk by reducing systemic ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

As the UK endures another harsh winter, plummeting temperatures and a surge in respiratory infections are placing strain on ...

Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...

Lower risk for COPD exacerbations seen with SGLT-2 inhibitors ... aged 40 years or older with T2D and active COPD who initiated treatment with SGLT-2is versus DPP-4is; GLP-1 RAs versus DPP-4is ...